Brisbane, Australia & Copenhagen, Denmark, September 22, 2014 - Clinical Network Services (CNS) Pty Ltd, an integrated service consultancy focused on product development, headquartered in Australia with offices in New Zealand, the UK and the USA and Ventac Partners, a dedicated life science consulting firm with offices in Europe, USA and Asia, today announced that they have signed a cooperative partnership agreement where CNS, and in particular the BioDesk consultancy, will become the preclinical, clinical and regulatory experts that Ventac can draw upon in support of portfolio companies and clients. Correspondingly, the multi-skilled team of Ventac Partners will be available to provide advice to clients of CNS in the various stages of fundraising, company evolution and drug-development pathways.
The partnership pools the corporate expertise of Ventac Partners with the regulatory expertise of CNS and expands the geographical reach of both.
The Managing Director of CNS, Russell Neal, commented, “We are absolutely delighted to be joining up with a life sciences investor and corporate consultancy of the standing of Ventac Partners. This agreement gives us greater access in particular with the US and Asian markets and we also hope that the corporate expertise of Ventac will be of benefit to our own client portfolio.”
Mikael Ørum, Co-Founder & Partner of Ventac Partners added, “We see Australia as an important market, particularly with the favourable tax and regulatory environment for clinical trials. CNS and BioDesk bring to our team top level regulatory expertise and clinical trial management, which will be of critical importance to our maturing portfolio and client companies.”
About Ventac Partners
The Ventac Partners team has a long-standing record of achievement; both from previous positions and as part of Ventac Partners, and all members bring extensive networks to academia, industry, and investors. Further information about Ventac Partners can be found at www.ventac-partners.com
About Clinical Network Services
Clinical Network Services (CNS) is an integrated service consultancy focused on product development, headquartered in Australia with offices in New Zealand, the UK and the USA. The Company provides a broad spectrum of services in the planning, implementation and delivery of product development programs and Phase 1 and 2 trials for small –medium sized biotechnology companies. CNS offers a unique service where it integrates BioDesk, an intelligent global product development (CMC, nonclinical and clinical aspects) and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. CNS’ regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.
CNS offers a uniquely differentiated, customer-orientated, suite of services to our clients which enables us to guide their products efficiently through critical post-discovery development and into initial human trials. CNS takes a global regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.
Further information about CNS and its intelligent development services can be found at www.clinical.net.au
Issued for and on behalf of CNS by Instinctif Partners.